Severe vulvovaginitis associated with intravaginal nystatin therapy.
A 64-year-old woman had severe vulvovaginitis develop while she was receiving intravaginal nystatin therapy for Candida glabrata infection. Mucocutaneous adverse effects have rarely been reported with nystatin despite long years of use. This complication should be included in the differential diagnosis of clinical failure of intravaginal nystatin therapy.
Dan
M
M
Clinic for Genitourinary Infections, Infectious Diseases Unit, E Wolfson Hospital, Holon 58100, Israel.
D000282:Administration, Intravaginal; D000893:Anti-Inflammatory Agents; D000935:Antifungal Agents / Q000008:administration & dosage / Q000009:adverse effects*; D001623:Betamethasone / Q000031:analogs & derivatives* / Q000627:therapeutic use; D002177:Candidiasis / Q000188:drug therapy; D004487:Edema / Q000139:chemically induced; D004890:Erythema / Q000139:chemically induced; D005260:Female; D006801:Humans; D006854:Hydrocortisone / Q000627:therapeutic use; D008875:Middle Aged; D009761:Nystatin / Q000008:administration & dosage / Q000009:adverse effects*; D014848:Vulvovaginitis / Q000139:chemically induced* / Q000188:drug therapy
D000893:Anti-Inflammatory Agents; D000935:Antifungal Agents; D009761:Nystatin; C011175:betamethasone-17,21-dipropionate; D001623:Betamethasone; D006854:Hydrocortisone